$3.20
2.56%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Stock price

$3.12
+0.05 1.63% 1M
+0.30 10.64% 6M
-0.29 8.50% YTD
+0.55 21.40% 1Y
-12.89 80.51% 3Y
-52.78 94.42% 5Y
-52.78 94.42% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.08 2.50%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $702.49m
Enterprise Value $243.99m
P/E (TTM) P/E ratio 3.85
EV/FCF (TTM) EV/FCF 2.61
EV/Sales (TTM) EV/Sales 0.42
P/S ratio (TTM) P/S ratio 1.20
P/B ratio (TTM) P/B ratio 0.97
Revenue growth (TTM) Revenue growth 910.33%
Revenue (TTM) Revenue $586.98m
EBIT (operating result TTM) EBIT $226.35m
Free Cash Flow (TTM) Free Cash Flow $93.37m
Cash position $498.85m
EPS (TTM) EPS $0.81
P/E forward negative
P/S forward 9.59
EV/Sales forward 3.33
Short interest 12.09%
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a CureVac N.V. forecast:

3x Buy
60%
1x Hold
20%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a CureVac N.V. forecast:

Buy
60%
Hold
20%
Sell
20%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
587 587
910% 910%
100%
- Direct Costs 136 136
14% 14%
23%
451 451
549% 549%
77%
- Selling and Administrative Expenses 47 47
20% 20%
8%
- Research and Development Expense 153 153
32% 32%
26%
251 251
191% 191%
43%
- Depreciation and Amortization 24 24
17% 17%
4%
EBIT (Operating Income) EBIT 226 226
174% 174%
39%
Net Profit 182 182
165% 165%
31%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
Seeking Alpha
11 days ago
CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Scientific Officer Axel Sven Malkomes - Chief Financial Officer Conference Call Participants Alec Stranahan - Bank of America Ryan McElroy - Lee...
Neutral
Accesswire
11 days ago
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precision immunotherapy CVGBM; Part B first data readout anticipated in H2 2025 Filed IND and CTA submissions for Phase 1 study with proprietary off-the-shelf program in squamous non-small cell lung cance...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 983
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today